Squawk Box Stocks Reports on: Herbalife Ltd. (NYSE: HLF), Nokia Corporation (NYSE: NOK), Vringo, Inc. (NYSE: VRNG), Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)

NEW YORK, NY -- (Marketwire) -- 02/19/13 -- Herbalife Ltd. (NYSE: HLF), Nokia Corporation (NYSE: NOK), Vringo, Inc. (NYSE: VRNG), Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM).

Herbalife Ltd. (HLF) saw shares gaining 1.23% to close at $38.74 on volume of 37,932,271 shares traded during Friday's trading session. Shares were well off their $44.93 high set during early morning trading on Friday as Carl Icahn disclosed owning a 13% stake in the company. Will shares continue to rise following this announcement or will Bill Ackman's bear case prove true in the end? Find out our thoughts on Herbalife in our exclusive report at: http://squawkboxstocks.com/report/HLF

Nokia Corporation (NOK) saw shares closing flat at $3.99 on volume of 25,802,490 shares traded during Friday's trading session. AdDuplex's February issue of Windows Phone usage stats showed that Nokia continues to dominate the WP market. According to the report, Nokia has a 78% share of the market, compared to HTC's 14% and Samsung's 6%. In the past three months, Nokia has managed to gain a couple of percentage points in market share at the expense of Samsung. Will investors turn their eyes to NOK on this positive report & send shares higher this week? Find out more in our exclusive report at: http://squawkboxstocks.com/report/NOK

Vringo, Inc. (VRNG) saw shares down 0.62% to close at $3.20 on volume of 1,619,206 shares traded. According to an SEC filing Mark Cuban, the billionaire owner of the Dallas Mavericks, raised his stake in the company. The SEC filing showed that Cuban increased his stake to 1.13 million shares from 1.03 million shares. Could additional, potentially larger purchases lead to more positive investor sentiment surrounding Vringo? Find out our thoughts on Vringo, Inc. in our exclusive report at: http://squawkboxstocks.com/report/VRNG

Peregrine Pharmaceuticals, Inc. (PPHM) saw its shares closing at $1.84 on volume of 3,167,818 shares traded during Friday's trading session. On Wednesday, the company announced results from its 70 patient open-label, randomized Phase II clinical trial of bavituximab used in combination with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer. The company saw its shares trade down nearly 25% following the results being published. Will shares of Peregrine bounce back to start the week? Find out our thoughts in our exclusive report at: http://squawkboxstocks.com/report/PPHM

About http://SquawkBoxStocks.com

Squawk Box Stocks offers its daily stock alerts and market content newsletter to investors looking for timely information available! Our experienced team provides you only the best stock alerts & research reports delivered to your email inbox for FREE. Our track record of providing winning alerts has won us the trust of thousands of investors worldwide. With our dedicated research team & investor database continuing to grow we have become a leading destination for the most profitable opportunities that are available in today's stock market. To receive our FREE, comprehensive newsletter, visit http://SquawkBoxStocks.com.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Winning Media LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.